In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Vir Biotechnology Inc’s stock clocked out at $5.13, up 0.20% from its previous closing price of $5.12. In other words, the price has increased by $0.20 from its previous closing price. On the day, 1.69 million shares were traded. VIR stock price reached its highest trading level at $5.155 during the session, while it also had its lowest trading level at $4.815.
Ratios:
To gain a deeper understanding of VIR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.25 and its Current Ratio is at 7.25. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Evercore ISI on September 03, 2025, initiated with a Outperform rating and assigned the stock a target price of $12.
On August 27, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $14.
JP Morgan Downgraded its Overweight to Neutral on January 29, 2024, whereas the target price for the stock was revised from $23 to $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 05 ’25 when de Verneuil Vanina sold 2,385 shares for $5.16 per share. The transaction valued at 12,307 led to the insider holds 78,210 shares of the business.
de Verneuil Vanina bought 2,385 shares of VIR for $12,307 on Nov 05 ’25. On Nov 03 ’25, another insider, de Verneuil Vanina, who serves as the EVP and General Counsel of the company, sold 1,365 shares for $5.86 each. As a result, the insider received 8,003 and left with 80,595 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 713711360 and an Enterprise Value of 307373408. For the stock, the TTM Price-to-Sale (P/S) ratio is 42.33 while its Price-to-Book (P/B) ratio in mrq is 0.90. Its current Enterprise Value per Revenue stands at 18.231 whereas that against EBITDA is -0.601.
Stock Price History:
The Beta on a monthly basis for VIR is 1.38, which has changed by -0.48024315 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, VIR has reached a high of $14.45, while it has fallen to a 52-week low of $4.16. The 50-Day Moving Average of the stock is -7.39%, while the 200-Day Moving Average is calculated to be -15.70%.
Shares Statistics:
It appears that VIR traded 1.45M shares on average per day over the past three months and 1396640 shares per day over the past ten days. A total of 139.02M shares are outstanding, with a floating share count of 92.68M. Insiders hold about 33.33% of the company’s shares, while institutions hold 56.95% stake in the company. Shares short for VIR as of 1760486400 were 10940671 with a Short Ratio of 7.56, compared to 1757894400 on 11852892. Therefore, it implies a Short% of Shares Outstanding of 10940671 and a Short% of Float of 12.690000000000001.
Earnings Estimates
The company has 5.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.69, with high estimates of -$0.6 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$3.36 and -$3.62 for the fiscal current year, implying an average EPS of -$3.53. EPS for the following year is -$2.92, with 8.0 analysts recommending between -$2.4 and -$3.63.
Revenue Estimates
In. The current quarter, 4 analysts expect revenue to total $1.16M. It ranges from a high estimate of $1.24M to a low estimate of $1M. As of. The current estimate, Vir Biotechnology Inc’s year-ago sales were $12.37MFor the next quarter, 4 analysts are estimating revenue of $2.36M. There is a high estimate of $4.5M for the next quarter, whereas the lowest estimate is $704k.
A total of 6 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $10M, while the lowest revenue estimate was $5.5M, resulting in an average revenue estimate of $6.84M. In the same quarter a year ago, actual revenue was $74.2MBased on 9 analysts’ estimates, the company’s revenue will be $10.94M in the next fiscal year. The high estimate is $20M and the low estimate is $3M.
